Combining GLP1-RAs with estrogen during the menopausal transition could help counteract the loss of estrogen’s protective effects against the development of MASLD, the hepatic manifestation of MetS, and enhance the efficacy of GLP1-RAs, particularly if treatment is initiated early. The gene discussed is GLP1R; the disease is metabolic syndrome.